Entera Bio Ltd. (NASDAQ:ENTX) Stock Has Average Price Target of $9.60

Key Points

• Analyst sentiment is moderately bullish: Six brokerages give Entera Bio a consensus “Moderate Buy” rating, with an average 12-month price target of $9.60 versus the stock’s recent $2.68 price.
• Entera Bio recently missed earnings expectations: The company reported a quarterly loss of $0.14 per share, below the consensus estimate of a $0.08 loss, and analysts expect a full-year loss of approximately $0.40 per share.
• The company is developing oral biologic medicines: Its pipeline includes oral parathyroid hormone treatments for osteoporosis and hypoparathyroidism, while institutional investors own 14.11% of the stock.

Shares of Entera Bio Ltd. (NASDAQ:ENTX - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the six brokerages that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, four have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $9.60.

Several equities analysts recently issued reports on the stock. UBS Group set a $9.00 price objective on shares of Entera Bio in a research note on Friday, September 18th. Wall Street Zen upgraded shares of Entera Bio to a "sell" rating in a research report on Saturday, August 8th. Guggenheim assumed coverage on shares of Entera Bio in a research note on Thursday, September 24th. They issued a "buy" rating and a $11.00 target price for the company. Leerink Partners began coverage on shares of Entera Bio in a research note on Friday, September 18th. They issued an "outperform" rating and a $9.00 target price for the company. Finally, Cantor Fitzgerald started coverage on Entera Bio in a report on Tuesday, September 22nd. They issued an "overweight" rating for the company.

Entera Bio Stock Performance

Shares of NASDAQ:ENTX opened at $2.68 on Monday. The business's fifty day moving average price is $2.88 and its two-hundred day moving average price is $2.02. The stock has a market cap of $466.11 million, a PE ratio of -7.66 and a beta of 1.40. Entera Bio has a one year low of $0.91 and a one year high of $4.20.

Entera Bio (NASDAQ:ENTX - Get Free Report) last released its quarterly earnings results on Friday, August 7th. The company reported ($0.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.06). As a group, equities research analysts predict that Entera Bio will post -0.40 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Entera Bio

A hedge fund recently raised its stake in Entera Bio stock. Seven Fleet Capital Management LP raised its stake in shares of Entera Bio Ltd. (NASDAQ:ENTX - Free Report) by 51.9% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 205,542 shares of the company's stock after purchasing an additional 70,224 shares during the period. Seven Fleet Capital Management LP owned 0.42% of Entera Bio worth $228,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 14.11% of the company's stock.

Entera Bio Company Profile

Entera Bio Ltd. is a clinical-stage biopharmaceutical company focused on developing orally delivered biologic medicines. The company's proprietary platform is designed to enable the oral administration of large-molecule therapies, including peptides and proteins that are traditionally delivered by injection.

Entera Bio's pipeline has included EB613, an oral formulation of parathyroid hormone fragment (teriparatide) being developed for the treatment of osteoporosis, and EB612, an oral parathyroid hormone product intended for hypoparathyroidism.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.